GlassScriptPhysician profile
Vinayak Nadar
NPI 1447645403
$3,278.73
in general payments reported to CMS, 2019-2025
14 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $219 · 2021: $594 · 2022: $480 · 2023: $797 · 2024: $790 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,101.07 | 2021-2024 | Senza |
| Medtronic, INC. | $913.21 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Collegium Pharmaceutical, INC. | $334.22 | 2023-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $258.64 | 2025 | Senza, Vyrsa V1, Vyrsa V1 |
| Medtronic USA, INC. | $188.17 | 2020 | |
| Vertos Medical, INC. | $110.07 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $109.00 | 2021-2022 | |
| Abbott Laboratories | $93.65 | 2023-2025 | Proclaim, Eterna |
| Tersera Therapeutics LLC | $51.88 | 2023-2025 | Prialt |
| Boston Scientific Corporation | $35.61 | 2024 | |
| Biodelivery Sciences International, INC. | $26.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.11 | 2021-2022 | |
| Pfizer INC. | $16.64 | 2020 | |
| Redhill Biopharma INC. | $14.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinayak Nadar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.